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Dyneinessential for the maintenance of cellular health. Here we review how autophagy
has fundamental functions in cellular homeostasis and possible uses as a therapeutic strategy for
neurodegenerative diseases associated with intracytosolic aggregate formation, like Huntington's disease
(HD). Drugs like rapamycin, that induce autophagy, increase the clearance of mutant huntingtin fragments
and ameliorate the pathology in cell and animal models of HD and related conditions. In Drosophila, the
beneﬁcial effects of rapamycin in diseases related to HD are autophagy-dependent. We will also discuss the
importance of autophagy in early stages of development and its possible contribution as a secondary disease
mechanism in forms of fronto-temporal dementias, motor neuron disease, and lysosomal storage disorders.
© 2008 Elsevier B.V.Open access under CC BY license.1. Protein degradation systems
The ubiquitin-proteasome system (UPS) and the autophagy-
lysosome pathway are the two main degradative pathways in
eukaryotes. Both of these systems are responsible for the efﬁcient
degradation and turnover of proteins within the cell. Failure of either
the UPS or autophagy has been associated with disease while the
upregulation of these processes has been shown to ameliorate certain
disease pathologies.
The proteasome is responsible for the selective degradation or
recycling of short-lived cytosolic and nuclear proteins, but also regulates
the turnover of some long-lived proteins. Attachment of a chain of at
least four covalently bonded ubiquitin molecules to a protein targets it
for degradation by the proteasome. The proteasome, a 2000 kDa,
multisubunit protein complex has a hollow barrel that contains its
proteolytic components. Because of the small size of the proteasome's
proteolytic core, client proteins generally require unfolding prior to
degradation. Due to the size of the narrow barrel of the proteasome and
the speciﬁcity of the process, many proteins are unable to be degraded
by the UPS, including oligomers or proteins in organelles [1].
Macroautophagy, more commonly referred to as autophagy, is
responsible for the bulk degradation of long-lived cytosolic proteins
and organelles. Unlike proteasomal degradation, autophagic degrada-
tion is thought to be largely non-speciﬁc. Degradation of macro-
molecules or organelles by autophagy requires the formation ofbinsztein).
 license.double-membrane vesicles called autophagosomes and subsequent
fusion of autophagosomes with lysosomes. This fusion produces an
autophagolysosome within which the cargo is degraded by acidic
lysosomal hydrolases.
2. Early studies in yeast
Despite an advanced understanding of the UPS, many aspects of
autophagy remain largely unknown. The discovery of pathways that
induce autophagy has contributed to the progression of our under-
standing of autophagy as a degradative pathway and its implications
in human health.
Autophagy is induced under starvation conditions, while it is
inhibited under nutrient-rich conditions [2,3]. An increase in protein
degradation during starvation allows the cell to survive stressful
conditions by providing nutrient turnover when extracellular nutri-
ents are scarce. Many of the earliest studies into the genetic control of
autophagy used viability during starvation as an assay to screen for
autophagy mutants in yeast [2,4–7]. Additionally, these screens and a
number of other labs exploited the simple yeast system to identify
new autophagy genes through a combination of morphological and
biochemical tools. Morphologically, the light microscope was used to
visualise the accumulation of vacuolar structures within cells under
starvation conditions, while biochemical analysis of the accumulation
of fatty acid synthase, an autophagy substrate, allowed researchers to
quantify autophagy function.
These early screens provided a foundation for the understanding of
autophagy in yeast and higher eukaryotes by identifying key proteins
and interactions. From the assessment of protein interactions and
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to consist of six main steps: induction, cargo selection and packaging,
autophagosome formation and completion, recycling of autophagy
regulators, fusion of the autophagosomewith the lysosome, and cargo
degradation. These steps rely on the function of key autophagy genes
(Atg genes) [8] and two highly conserved ubiquitin-like conjugation
reactions, Atg12–Atg5 [9,10] and Atg8-phosphatidylethanolamine
(PE) conjugation [8,11,12]. The Atg12–Atg5 complex can additionally
bind Atg16 whichmediates the formation of tetrameric and octameric
complexes of Atg12–Atg5–Atg16 [13,14]. The function of this large
molecular structure is important to autophagosome membrane
formation and has been implicated in stabilisation of the Atg8–PE
complex, the other important conjugation system [15]. Atg8, referred
to as microtubule associated protein 1 light chain 3 (LC3) in mammals,
undergoes a similar but reversible conjugation reaction with phos-
photidlyethanolamine (PE). This reaction lipidates the cytosolic LC3-I
isoform, forming LC3-II, an autophagosomemembrane-bound protein
[16]. LC3-II is the only protein known to remain attached to the
membrane after complete formation of the autophagosome and
therefore is a robust marker of autophagosome number. Changes in
steady-state LC3-II levels provide both a surrogate for autophagosome
number and an idea as to where these effects occur in the progression
of autophagy.
3. Autophagy in development
In light of the importance of the degradative pathways in
mammalian disease, a branch of autophagy research has studied the
role of autophagy in normal development and maintenance of health.
It has been shown that autophagy is important during critical
developmental stages in which nutrients are restricted. Termination
of the direct fetal nutrient supply from the mother presents a stressful
situation for the newborn infant. During this transition period,
autophagy provides the necessary nutrients to the infant through
increased turnover of proteins. This has been shown experimentally in
a transgenic mouse model expressing GFP fused LC3 to visualise
autophagosomes in vivo [17]. In these mice, autophagosome forma-
tion was increased naturally within 30 min after birth, peaked around
6 h after birth, and declined back to basal levels within 24 to 48 h.
These observations support the role of autophagy as a means of
increasing newly-available nutrients in a nutrient deprived environ-
ment. Thereby, neonates are able to cope with severe starvation after
birth by the induction of autophagy and turnover of proteins.
To assess the speciﬁc role of autophagy, Mizushima's and Tanaka's
groups studied the effect of starvation during this critical period in
Atg5 and Atg7 knockout mice, i.e. autophagy-deﬁcient mice. These
mice develop normally with only a slightly lower birth weight for the
Atg5−/− mice and a signiﬁcant weight reduction in the Atg7−/− mice.
Atg5 [17] and Atg7 [18] knockout mice die within one day of birth.
Under forced starvation conditions, Atg5 and Atg7 knockout mice die
within half the time (12–13 h) of their Atg5+/− or wildtype littermates
(21–24 h). These experiments support the role of autophagy in normal
developmental processes that occur in the absence or diminished
levels of nutrient supply, lending further importance to the need for
the functional turnover of amino acids.
As a systemic deﬁciency of autophagy genes in these mice causes
neonatal death within a day of birth, conditional autophagy-deﬁcient
mice were generated to assess the role of autophagy in homeostasis
of various tissues later in development. In the absence of a
predisposition to genetic disease, both Atg5 and Atg7 conditional
knockout mice and ubiquitous knockout mice develop ubiquitinated
protein aggregates and varying degrees of tissue deterioration.
Conditional Atg5 and Atg7 knockout mice suffer not only from
nutrient deprivation during starvation periods but also develop
dysfunctional hepatic tissue and progressive neurodegeneration [17–
19]. Loss of Atg5 speciﬁcally in neural tissue of 10.5 day old miceresults in growth retardation, weight loss, an accumulation of
ubiquitin-positive proteins, motor impairment and progressive
neurodegeneration. Within hepatocytes, conditional Atg5 knockout
mice develop diffuse abnormal protein deposits which progress to
inclusion bodies 16 days after induced knockdown [20]. Similar
conditions developed in hepatocytes of Atg7 conditional knockout
mice. A nearly six-fold enlargement of the liver was accompanied by
the accumulation of ubiquitin-positive inclusions within the cytosol
of hepatocytes and defective cellular organelles such as mitochon-
dria, ER and peroxisomes.
A recent study analysed the role of p62/A170/SQSTM1 in relation to
inclusion formation in autophagy-deﬁcient mice. Loss of p62 in
autophagy-deﬁcient mice decreased levels of polyubiquitinated
proteins and inclusions. The authors suggested that this was because
p62 was a key mediator of inclusion formation [21]. Interestingly,
similar conclusions were deduced from a parallel study of the Droso-
phila p62 orthologue in autophagy-deﬁcient ﬂies [22].
Additional characterisation of autophagy deﬁciency has been
performed in Atg7 Drosophila melanogaster mutants. Although Atg7
mutant ﬂies aremorphologically normal, they are sensitive to stressful
conditions and show a decreased level of cell death-induced
autophagy during metamorphosis, a necessity during normal devel-
opment [23]. Increased lethality and a decrease in GFP-LC3 levels in
Atg7 deﬁcient ﬂies indicated that autophagy deﬁciency was deleter-
ious during stress-inducing conditions such as starvation, oxidative
stress and metamorphosis. Similar to Atg7-deﬁcient mouse models,
these ﬂies develop large inclusion bodies and accumulate ubiquiti-
nated proteins within neurons, in addition to a shortened life span
under unstressed conditions. Motor function, as measured in climbing
assays, progressively worsens in these ﬂies, an indicator of reduced
neuronal function.
Studies in Drosophila have also contributed to an understanding of
the roles autophagy may play in ageing. Atg8a mutant ﬂies have
reduced lifespan, while transgenic overexpression of Atg8a extends
the ﬂy lifespan by 56% and increases its resistance to oxidative stress
and reduces the accumulation of ubiquitinated proteins [24].
4. Autophagy deﬁciency: a secondary disease mechanism
in neurodegeneration
Autophagosomes need to ultimately fuse with lysosomes. The
endocytic pathway is necessary for maturation of autophagosomes via
the fusion of autophagosomes with endosomes, prior to autophago-
some–lysosome fusion [25]. The cytoskeleton maintains the spatial
organisation of autophagy by conducting the trafﬁcking of organelles
involved in different interactions during autophagy. Many of the
pathways that contribute to autophagy have only recently been
identiﬁed and it is expected that autophagy interacts with numerous
other systems either through its own progression or by the
intracellular signals that control autophagic activity. From this
understanding of autophagy as a dynamic integrator of numerous
signalling pathways, it is evident that disruptions in the functionality
of other pathways are likely to disrupt autophagy and therefore
cellular homeostasis. The most recent research within the ﬁeld has
raised the idea of the role of compromised autophagy in the
progression of disease. A number of diseases have been shown to
manifest a deﬁciency in autophagy, identifying autophagy as an
important secondary disease mechanism.
5. Dynein
The relay of signals within and between cells is dependent upon
efﬁcient internal transport. Neuronal cells are particularly dependent
on the accurate and timely conversion of external stimuli to an
intercellular response via the movement of internal cargo. Directed
movements over long distances, such as that seen in motor neurons,
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Dyneins move cargo centripetally towards the minus-end of micro-
tubules, i.e. towards the microtubule organising centre near the
nucleus. Plus-end-directed kinesins move cargo in the opposite
direction, centrifugally, outwards into the cytoplasm and the plus-
end of microtubules (reviewed in [26]).
Autophagic ﬂux is microtubule-dependent, as depolymerisation of
microtubules with nocodazole inhibits the fusion of autophagosomes
with lysosomes [27,28]. Depolymerisation of microtubules results in a
decrease in the clearance of autophagy substrates [29]. Under these
conditions, autophagosome maturation [30,31] and autophagosome–
lysosomal fusion are decreased, as autophagosomes are unable to
shuttle from the cell periphery to the MTOC via microtubules [32].
Knock down of dynein shows similar effects, suggesting that dyneins
are the key motor proteins that trafﬁc autophagosomes along
microtubules towards lysosomes [32]. It is unclear how dyneins are
connected to the autophagy machinery. However, HDAC6, a cytosolic
histone deacetylase-like protein is associated with microtubules and
appears to be a modulator of autophagy [33,34]. While its mode of
action remains unclear, it is possible that it is involved in autophago-
some trafﬁcking on microtubules.
A number of mutations affecting microtubule transport have been
implicated in the development of motor neuron diseases (MND) in
mouse models [35–37] and humans [38]. Motor neuron disease refers
to a group of sporadic and familial diseases characterised by the
degeneration of motor neurons. Disruption of retrograde axonal
transport of cargo by overexpression or depletion of dynein complex
components in transgenic mice results in the progressive degenera-
tion of motor neurons and the formation of inclusions [35,37]. The
pathology and symptomatic progression of the disease in these
transgenic models mimic those seen in some MND patients. Interest-
ingly, the presence of aggregates in MND models may hint at a
deﬁciency in autophagy as a secondary disease mechanism in these
disorders. As disruption in dynein-dependent transport is implicated
in the cause of this group of diseases, it is likely that the aggregation of
substrates seen in mousemodels could, at least, in part result from the
disruption of the microtubule-dependent movement of autophago-
somes, autophagosome maturation, and autophagosome–lysosome
fusion. Indeed, an increase in autophagosome number and LC3-II
levels can be observed in dynein-deﬁcient transgenic mice [29,39].
Further research will be needed to clarify the signiﬁcance of
autophagy dysfunction in MND, particularly in forms not due to
primary mutations of the dynein machinery.
6. The ESCRT complex
The turnover and recycling of integral membrane proteins from the
plasma membrane is carried out largely by different functions of the
endocytic pathway. Simple sorting by endosomes recycles proteins,
returning them to the plasma membrane. A more intricate degrada-
tive system utilises the multivesicular body (MVB), a specialised
vesicular structure generated by invagination of the endosomal
membrane to form lumenal vesicles. The fusion of MVBs with
lysosomes releases the vesicles into the acidic lumen of the lysosomes
within which hydrolases degrade the vesicles and their cargo. The
sorting of integral membrane proteins into the MVB pathway is
dependent upon monoubiquitination of the protein, a signal that
destines the protein for incorporation into the lumenal vesicles of
MVBs [40–44]. The ﬁdelity of this process from protein sorting to
endosomal-lysosomal fusion is maintained by the sequential interac-
tion of four complexes termed the endosomal sorting complexes
required for transport (ESCRT complexes). The speciﬁc interactions of
these complexes are necessary for the formation of the MVB and
proper progression of endosomal–lysosomal fusion (reviewed in [45]).
Each of the ESCRTs is recruited to their particular function through
multiple interactions with proteins, membranes, endosomes, andother ESCRTs. Early cargo sorting is carried out by the interactions of
ESCRT-0, -I, and -II with ubiquitinated cargo. ESCRT-III is required for
disassembly of the ESCRT complex and recruitment of de-ubiquitilat-
ing enzymes (DUBs) to remove ubiquitin from the cargo prior to
degradation. The ﬁnal actions of ESCRT-III concentrate cargo in late
endosomes.
In addition to known roles in HIV budding [46] and tumour
suppression [47–49], the ESCRT machinery has been implicated
recently in neurodegenerative disorders, such as frontotemporal
dementia linked to chromosome 3 (FTD3) [50] and amyotrophic
lateral sclerosis (ALS) [51,52]. Despite the association of speciﬁc
ESCRT machinery mutations with neurodegenerative disorders, the
mechanism of disease remains largely unknown. A point mutation in
the ESCRT-III subunit CHMP2B that alters a splice-site within the
gene was found to be associated with a rare familial autosomal
dominant form of FTD3 [50]. Additionally, two different point
mutations in CHMP2B have also been associated with a non-SOD1
form of ALS [52,53].
Expression of a deletion mutant of CHMP2B, synonymous to the
splice mutant, increases neuronal and dendritic loss through an
apoptosis-independent pathway [54]. As autophagosomes are
thought to fuse with endosomes or MVBs prior to fusion with
lysosomes, recent studies have looked at the effect of the CHMP2B
deletion mutant on autophagy [54,55]. Within cell and ﬂy models,
expression of this deletion mutant increased LC3-II levels, caused an
accumulation of autophagosomes, and decreased the formation of
MVBs. Experimental characterisation of CHMP2B and a mutant form
of SKD1 [56] (ﬁrst shown with the yeast homologue Vps4 [57]) that
prevents dissociation of the ESCRT-III complex prior to the next round
of endocytic cargo sorting, indicates that the proper dissociation of the
ESCRT-III complex is critical to both autophagosome maturation and
proper fusion of autophagosomes with lysosomes. ESCRT dysfunction
has been shown to cause an accumulation of autophagosomes in
cortical neurons and ﬂies [54].
The effect of ESCRT dysfunction on autophagy has been studied by
the expression of mutants or the knockdown of genes in all three
complexes and associated proteins: (associated proteins (SKD1/Vps4
[56,57], fab1 [58]), ESCRT-III-CHMP2B [54,55], mSnf7-2/Vps32 [54,58],
Vps24 [55]), (ESCRT-II-Vps25 [58], Vps22 [55]), and (ESCRT-I-Vps28
[58], Tsg101/Vps23 [55]). Data accumulated from studies of loss-of-
function of various ESCRT genes in a wide range of cell types, suggest
that these defects result in deﬁcient maturation of autophagosomes or
in their inability to fuse with lysosomes and endosomes. Autophago-
somes accumulate without degradation of their cargo leading to
neurodegeneration in many cases. Additionally, many of these tissues
display an increase in polyubiquitinated inclusions. It remains unclear
whether this deﬁciency in autophagy is a direct effect of the
disruption of the ESCRT complex on autophagosomes or indirect via
endosomes and lysosomes. Overall, recent research suggests that the
deﬁciency in autophagy caused by ESCRT dysfunction contributes to
the neurodegeneration in FTD3 and ALS as a secondary disease
mechanism.
7. Lysosomal storage disorders
The role of lysosomes in autophagy has been well characterised
from an early point in autophagy research [59]. Fusionwith lysosomes
is necessary for the degradation of autophagy cargo by the lysosomal
acidic hydrolases. Without this fusion event autophagosomes accu-
mulate with undegraded cargo, thus increasing the toxic species
within cells. Recent research suggests that this defect may be
characteristic of a group of neurodegenerative diseases referred to
as lysosomal storage disorders [60].
Lysosomal storage disorders (LSDs) are a group of at least 40
neurodegenerative or myopathic diseases deﬁned by the accumula-
tion of undegraded lysosomal substrates within the lysosomal lumen
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mutations that lead to complete or partial dysfunction of lysosomal
proteins (typically lysosomal hydrolases). It has been estimated that
lysosomes contain 50–60 different hydrolases [62] that are active
within the acidic pH of the lysosomal lumen. In addition to a number
of hydrolases, multiple integral membrane proteins have been
identiﬁed, most with no known function [63]. Despite the large
differences in the pathology of these diseases, at a molecular level all
of these diseases result in the accumulation of undegraded cargo both
within the lysosomal lumen and outside lysosomes. As it is clear that
this accumulation affects numerous other pathways, it is not known
which species and pathways contribute most signiﬁcantly to the
progression of these diseases (reviewed in [61,64]).
The current understanding of autophagy and its dependence upon
lysosomes has led researchers to study the effects of LSDs on both
basal autophagy and the induction of autophagy. Fusion of autopha-
gosomes with lysosomes is necessary for the degradation of cargo by
the lysosomal acidic hydrolases. Without this fusion event autopha-
gosomes and their cargo accumulate, thus increasing toxic species
within cells. A recent study [60] identiﬁed an inhibition of autophagy-
dependent protein degradation in amousemodel ofmultiple sulfatase
deﬁciency (MSD) and mucopolysaccharidosis type IIIA (MPS-IIIA).
MSD, an aggressive neurodegenerative disorder that results in death,
is caused by a mutation in the sulfatase modifying factor 1 (SUMF1)
gene which encodes the formylglycine-generating enzyme (FGE)
[65,66]. FGE is required for posttranslational activation of sulfatases.
Without this modiﬁcation, sulfatase activity is impaired and the
enzymes are therefore unable to degrade lysosomal contents. In
addition to an accumulation of lysosomes and undegraded lysosomal
substrates, MSD mice accumulated autophagosomes. Elevated LC3-II
levels detected by immunoblotting and LC3-positive vesicles in
neuronal tissue conﬁrmed an accumulation of autophagosomes.
Analysis of cell lines derived from MSD mice and their wildtype
littermates showed a decrease in the colocalisation of the lysosomal
marker, LAMP1, and LC3 in MSD mouse embryonic ﬁbroblasts (MEFs).
This indicates that the accumulation of autophagosomes results from
failed fusion of autophagosomes with lysosomes. The mutation of
SUMF1 inMSDmice prevents both the degradation of lysosomal cargo
and the fusion of autophagosomes with lysosomes. The accumulation
of the autophagy substrates within MSD MEFs further supports a
deﬁciency in autophagy as a secondary disease mechanism in LSDs.
Brain tissue of MSD mice showed an accumulation of ubiquitinated
aggregates.
These examples suggest that autophagy deﬁciency may be an
important secondary disease mechanism in a range of conditions.
8. Induction of autophagy as a therapeutic for neurodegenerative
disorders
Intracellular protein misfolding/aggregation are features of many
late-onset neurodegenerative diseases, called proteinopathies. These
include Alzheimer's disease, Parkinson's disease (PD), tauopathies,
polyglutamine expansion diseases – such as Huntington's disease
(HD) – and various spinocerebellar ataxias (SCAs), like SCA3.
Currently, there are no effective strategies to slow or prevent the
neurodegeneration or muscular dystrophy resulting from these
diseases in humans. Due to the size of the narrow barrel of the
proteasome and speciﬁcity of the process, most large aggregate-prone
proteins are precluded from entering the structure [1]. We discovered
that aggregate-prone species of proteins like mutant huntingtin have
a high dependency on autophagy for their clearance, while wild-type
species do not rely on autophagy for their degradation [67–71].
Inhibition of autophagy by chemical regulators, such as baﬁlomycin
A1 and 3-methyladenine, decreases the clearance of aggregate-prone
proteins such as mutant huntingtin (that causes Huntington's disease)
or mutant forms of alpha-synuclein that cause familial Parkinson'sdisease. This results in an increase in the number of huntingtin
aggregates in mammalian cells [67,68,71].
The discovery of target of rapamycin (TOR) as a pivotal regulator
of autophagy induction in eukaryotes [72], pushed the scope of
autophagy research from its fundamental function in cellular health
and homeostasis to a possible therapeutic. An understanding of the
function of TOR function as a negative regulator of autophagy
allowed researchers to exploit rapamycin, an inhibitor of TOR, as a
means to induce autophagy. Rapamycin induces autophagy in
species from yeast to mammals and appears to have this effect in
all mammalian cells tested to date. Chemical induction of autophagy
by rapamycin enhanced clearance of aggregate-prone proteins and
reduced the number of aggregates [71]. Additionally, amelioration of
neurodegenerative symptoms by autophagy induction has been seen
in both a Drosophila HD model and transgenic HD mice [70]. It is
likely that this autophagic clearance is speciﬁc to the smaller
oligomeric and monomeric precursors of aggregates, not the large
inclusions [73].
These ﬁndings are replicable in other proteinopathy models. For
instance, rapamycin reduces toxicity and enhances clearance of
aggregate-prone proteins, like a polyalanine expansion protein and
tau (associated with front-temporal dementia or tauopathy). These
results provide proof-of-principle in the ability of autophagy to clear
aggregate-prone proteins [52,74] and suggest a druggable target
pathway which may ameliorate symptoms or prevent disease.
Importantly, the effects of rapamycin in ﬂy models of these diseases
appear to be autophagy-dependent, as rapamycin had no effects on
proteinopathy toxicity in ﬂies expressing these mutant proteins on a
background of reduced activity of different autophagy genes [52,75].
Unfortunately, long-term use of rapamycin can cause adverse side
effects such as poor wound-healing and general immunosupression.
Mammalian target of rapamycin (mTOR) regulates a range of
pathways (such as translation of certain proteins, cell division, etc.),
and its major side-effects can be attributed to autophagy independent
pathways. Also, how mTOR regulates mammalian autophagy is still
not understood. Further insight into how this occurs will hopefully
provide safer, more speciﬁc druggable targets suitable for long-term
treatment.
Currently, there exist very few pharmacological treatment options
for neurodegenerative proteinopathies. The disaccharide trehalose
has also been shown to reduce aggregation and induce autophagy in
an mTOR-independent manner, but this process and the pathway
through which it acts remain unknown [76,77]. Recently, an mTOR-
independent pathway for autophagy induction has been discovered:
inhibition of inositol monophosphatase (IMPase) reduces free inositol
and myoinositiol-1,4,5-triphosphate (IP3) levels which lead to an
upregulation of autophagy. Lithium, carbemazepine and valproate,
drugs used to treat a range of neurological and psychiatric conditions,
induce autophagy via this pathway. Like rapamycin, these drugs
increase the clearance of aggregate-prone proteins like mutant
huntingtin and have beneﬁcial effects in ﬂy models of HD [78–80].
Further studies have shown that this pathway is regulated by
intracellular calcium levels and cAMP, and revealed additional drugs
that may induce autophagy, including comparatively safe drugs that
act on the brain, such as verapamil (an L-type calcium channel
antagonist) and clonidine (an imidazoline receptor agonist that
reduces cAMP levels) [81]. Proof-of-principle for these drugs has
been provided in cell, Drosophila and zebraﬁsh models of HD.
A recent study has shown tantalising effects of lithium in the
treatment of amyotrophic lateral sclerosis (ALS) in humans andmouse
models of this disease. Lithium carbonate (when given in addition to
the benchmark drug riluzole), signiﬁcantly delayed the onset of
disability and death in human ALS patients, compared to those
administered riluzole alone. Treatment of G93A ALSmicewith lithium
carbonate delayed death and onset of disease progression. Tissue
collected from these mice showed an increase autophagic activity and
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synuclein accumulation [82]. This signiﬁcant correlation between
autophagy induction and the delay of disease progression is
compatible with our previous data showing that autophagy induction
may protect against a range of neurodegenerative diseases caused by
aggregate-prone proteins. Combination therapies utilising rapamycin
plus a drug acting on an mTOR independent pathway may provide
more effective treatments for neurodegeneration by providing an
additive effect on autophagy induction while reducing the adverse
side effects of rapamycin treatment alone.
9. Conclusion
Today 31 genes have been identiﬁed that play a speciﬁc role in the
normal function of autophagy [83]. At least eight of these genes
contribute to two conjugation reactions important for the formation
of the autophagosome. As the understanding of autophagy has
progressed, so have the available techniques and autophagy assays
[84]. As our understanding of the autophagy machinery progresses,
more advanced techniques will allow us to assess autophagy more
precisely.
The progression of research in the ﬁeld of autophagy has taken
the understanding of autophagy from a means of survival during
starvation to a possible means of treating neurodegeneration
pharmacologically. Progress in the understanding of autophagy has
emphasised the importance of autophagy in cellular homeostasis,
adaptation to starvation, prevention of neurodegeneration in animal
models, and the signiﬁcance of its deﬁciency in the development of
neurodegenerative disorders. The overall relevance of autophagy in
disease far exceeds the breadth of this review. With its implicated
roles ranging from viral infection and cancer to liver and cardiac
diseases (reviewed in [73]), autophagy's importance in the main-
tenance of health is just beginning to be realised. Alongside
understanding its implications in disease, future research will need
to focus on a more complete characterisation of the autophagy
machinery and how it responds to autophagy-regulating signalling
pathways. This may provide further insights into the role that
autophagy has in disease and how it may be possibly utilised as a
therapeutic strategy.
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